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THE JOHN WESLEY POWELL STUDENT RESEARCH CONFERENCE· APRIL 1996 
Poster Presentation 1 
THE "COMBINED" 192 IGG SAP ORIN LESION APPROACH AS AN 
ANIMAL MODEL OF ALZHEIMER'S DISEASE 
Katharine Trickle and Wayne Dornan*, Department of Psychology, IWU 
While significant progress has been made toward an understanding of the 
etiology of AD, presently no reliable animal model exists that mimics the 
profound pathological and behavioral changes that characterize the disease. 
Accumulating evidence from a large number of studies conducted in the rat 
reveal that disruption of the functional integrity of the cholinergic basal 
forebrain projection to the hippocampus and cortex using cholinergic 
antagonists or specific lesions of the medial septal area (MSA) and nucleus 
basalis magnocellularis (NBM) induce marked impairments on a variety of 
behavioral tasks, particularly those that involve spatial learning (e.g. Morris 
water maze, and radial arm maze). Recently, 192 IgG saporin has been has 
been reported to be a selective cholinergic neurotoxin. Unilateral injections of 
192 IgG saporin into the lateral ventricles induce a 80-90% reduction of 
acetylcholine levels in the cortex and hippocampus. Although several studies 
have reported an impairment of spatial learning following intraventricular 
injections of saporin, all have noted that the effects observed may be due to 
loss of cerebellar Purkinje cells damaged following intraventricular (i.c.v. ) 
injections of 192 IgG saporin. Indeed, in a recent article published by Walsh, 
Kelly, Dougherty, Stackman, Wiley, and Kutscher in the journal Brain 
Research (702: 233-245, 1995) the authors conclude that although 192 IgG 
saporin is a highly selective cholinergic toxin, the secondary effects induced 
by i.c.v. injections of 192 IgG saporin " makes the i.c.v. model of 192 IgG­
saporin problematic for studying the role of the cholinergic basal forebrain 
(CBF) in normative behavior and in disease states ". The authors further 
suggest that site-specific injections of 192 IgG saporin would provide a viable 
approach to model Alzheimer's disease. In order to circumvent the problem of 
cerebellar Purkinje cell damage following i.c.v. injection of 192 IgG saporin, 
while at the same time producing a cholinergic lesion that essentially 
destroys 80 -90 % of the cholinergic input to the hippocampus and cortex in 
the rat, we have employed a "combined lesion" technique where animals 
receive three injections of 192 IgG saporin into the medial septal area, and 
two (bilateral) injections into the nucleus basalis magnocellularis. In a series 
of studies that will be presented at this conference, the effects of this 
"combined " lesion approach on spatial learning in the rat will be reported. 
We hope that the "combined lesion model " using 192 IgG-saporin by 
circumventing the inherent problems associated with i.c.v. injections of 
saporin may provide an avenue to test novel therapeutic drugs to be used as a 
palliative treatment for Alzheimer's disease. 
